Cagrilintide

What is Cagrilintide?

Cagrilintide is a synthetic peptide designed to emulate the effects of amylin, a hormone co-secreted with insulin by pancreatic β-cells. Amylin plays a crucial role in regulating appetite and food intake. Cagrilintide’s extended half-life allows for once-weekly administration, making it a promising candidate for the treatment of obesity and type 2 diabetes. This peptide is intended solely for scientific investigation and is not approved for human or veterinary use.

Structure

• Amino Acid Sequence: XKCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP
• Chemical Formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂
• Molecular Weight: 4409.01 g/mol
• Synonyms: AM833, ATC-161

Cagrilintide Research

Cagrilintide in Weight Management

Clinical trials have demonstrated that cagrilintide significantly reduces body weight in individuals with overweight and obesity. A phase 2 trial reported dose-dependent weight loss, with higher doses leading to more substantial reductions. The study concluded that cagrilintide was well-tolerated and effective in promoting weight loss. [1]

Cagrilintide and Type 2 Diabetes

Research indicates that cagrilintide may improve glycemic control in individuals with type 2 diabetes. A study assessing the co-administration of cagrilintide with semaglutide found significant reductions in HbA1c levels and body weight compared to monotherapy. These findings suggest potential benefits in combining these agents for enhanced metabolic outcomes. [2]

Combination Therapy: Cagrilintide and Semaglutide (CagriSema)

The combination of cagrilintide and semaglutide, known as CagriSema, has been investigated for its synergistic effects on weight loss and glycemic control. Clinical trials have shown that CagriSema leads to greater weight loss compared to either agent alone, positioning it as a promising therapy for obesity and type 2 diabetes management. [3]

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Referenced Citations

Referenced Citations

1. Lau DCW, Erichsen L, Francisco AM, et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” The Lancet. 2021;398(10317):2160–2172. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2901751-7/abstract
2. Frias JP, Deenadayalan S, Erichsen L, et al. “Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” The Lancet. 2023;402(10397):1977–1990. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2901163-7/fulltext\
3. Novo Nordisk A/S. “CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial.” Company Announcement. December 20, 2024. Available at: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915082